Reata Pharmaceuticals News

RETADelisted Stock  USD 109.67  3.31  2.93%   
About 61% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at thelincolnianonline.com         
Reata Pharmaceuticals Set to Announce Quarterly Earnings on Friday
news
over a year ago at Macroaxis         
Do analysts believe Reata Pharmaceuticals (USA Stocks:RETA) will continue to rise?
Macroaxis News
over a year ago at benzinga.com         
Benzingas Stock Whisper Index 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
benzinga news
over a year ago at bizjournals.com         
Plano-based Reata Pharmaceuticals secures FDA approval for first-of-its-kind ultra-rare disease trea...
bizjournals News
over a year ago at fool.com         
Why Reata Pharmaceuticals Stock Skyrocketed This Week
fool News
over a year ago at zacks.com         
Reata Stock Jumps as FDA Approves Rare Disease Drug
zacks News
over a year ago at marketwatch.com         
Reatas new rare-disease drug will cost 370,000 per year
marketwatch News
over a year ago at marketwatch.com         
Reatas new rare-disease drug will cost 370,000 per year
marketwatch News
over a year ago at finance.yahoo.com         
Pharma Stock Surges After FDA Approves Treatment
Yahoo News
over a year ago at benzinga.com         
Heres How Much You Would Have Made Owning Reata Pharmaceuticals Stock In The Last 5 Years
benzinga news
over a year ago at benzinga.com         
Reata Pharmaceuticals Gets Price Target Bumps By Analysts Following FDA Approval Of Skyclarys
benzinga news
over a year ago at fool.com         
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
fool News
over a year ago at investorplace.com         
Why Is OKYO Pharma Stock Down 31 percent Today?
sbwire news
over a year ago at marketwatch.com         
Reatas stock jumps 175 percent in premarket trading after FDA approval
marketwatch News
over a year ago at marketwatch.com         
Reatas stock jumps 175 percent in premarket trading after FDA approval
marketwatch News
Far too much social signal, news, headlines, and media speculation about Reata Pharmaceuticals that are available to investors today. That information is available publicly through Reata media outlets and privately through word of mouth or via Reata internal channels. However, regardless of the origin, that massive amount of Reata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Reata Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Reata Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Reata Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Reata Pharmaceuticals alpha.

Reata Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
After Pfizer-Seagen deal, analysts expect more MA activity - FiercePharma
05/09/2023
2
The one-year returns have been splendid for Reata Pharmaceuticals shareholders despite underlying losses increasing
06/07/2023
3
TD Cowen starts Reata at outperform, cites sales potential of ataxia drug
07/06/2023
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance